Parkinson's Breakthrough

A new pill called solengepras has shown promise in reducing symptoms of Parkinson's disease, with patients experiencing 37 minutes less 'off' time per day. The drug works by blocking a receptor that slows down movement, rather than increasing dopamine levels.

Parkinson's Breakthrough
Photo: The Independent

A clinical trial involving 341 patients with Parkinson's disease has found that solengepras significantly reduces 'off' time, a period when medication wears off and symptoms return or worsen. Patients taking the higher dose of solengepras experienced 37 minutes less 'off' time per day compared to those taking a placebo.

The trial, which was conducted across the US, Europe, UK, and Australia, also found that patients taking solengepras had improved mobility and were able to perform daily tasks more easily. They also experienced fewer movement problems, known as dyskinesia.

Solengepras works by blocking a receptor called GPR6, which acts as a brake on movement when dopamine levels are low. By blocking this receptor, the drug helps to improve mobility in patients with Parkinson's disease.

The developer of the drug, Cerevance, says that the results offer great hope for future treatments. The company plans to discuss the results with the US Food and Drug Administration to determine the next steps.

Parkinson's disease is a progressive brain condition that affects over 10 million people worldwide. Current treatments focus on increasing dopamine levels in the brain, but these can have side effects such as nausea, hallucinations, and involuntary movements.

The new drug could potentially offer a new approach to treating Parkinson's disease, with fewer side effects. The trial results are expected to be shared with regulators, who will consider approving the treatment for use in the UK within three years.

Key facts

  • Solengepras reduces 'off' time in Parkinson's patients by 37 minutes per day
  • The drug works by blocking a receptor called GPR6, which slows down movement
  • Patients taking solengepras experienced improved mobility and fewer movement problems
  • The trial involved 341 patients across the US, Europe, UK, and Australia

Three perspectives

Neutral

The results of the clinical trial offer a promising new approach to treating Parkinson's disease. However, further testing and regulatory approval are needed before the drug can be made available to patients. The next steps will depend on discussions between the developer and regulatory authorities.

Positive

The new drug could potentially offer a significant improvement in the quality of life for patients with Parkinson's disease. By reducing 'off' time and improving mobility, solengepras could help patients to perform daily tasks more easily and maintain their independence.

Negative

While the results of the trial are promising, there are still potential risks and side effects associated with the new drug. Some patients experienced headaches and urinary tract infections during the trial, and further testing is needed to fully understand the safety and efficacy of solengepras.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Study identifies racial differences in pancreatic cancer tumor cells
Next storyStudy identifies racial differences in pancreatic cancer tumor cells

All sections

Edition